The HERACLES-A, a multicenter open-label phase II trial (HER2 Amplification for Colorectal Enhanced Stratification), used trastuzumab plus lapatinib in HER2-positive KRAS exon 2 WT advanced CRC patients who were resistant to first-line treatments, including cetuximab [138]. This evidence concerns the gene KRAS and colorectal carcinoma.